Skip to main content
Premium Trial:

Request an Annual Quote

Personal Genome Diagnostics Inks Cancer Genomic Profiling Deal with Duke University Health System

NEW YORK — Personal Genome Diagnostics said on Tuesday that it has signed an agreement to provide its Elio Tissue Complete next-generation sequencing test platform to the Duke University Health System Clinical Molecular Diagnostics Laboratory.

Elio Tissue Complete is a US Food and Drug Administration-cleared 507-gene panel kit that identifies single-nucleotide variants, small insertions and deletions, amplifications, rearrangements, microsatellite instability, and tumor molecular burden in DNA from patient tissue samples.

According to Personal Genome Diagnostics, or PGDx, the platform will be integrated into the Duke lab and be used as its primary technology for clinical oncology genomic testing initiatives. As part of the deal, the Baltimore-based company and DUHS will collaborate on a data integration system to join the health system's electronic health records with other local systems.

Financial and other terms of the collaboration were not disclosed.

"We believe strongly that the ability to provide accurate, rapid genomic profiling data and insights that can be easily accessed and incorporated into existing cancer care pathways will allow our clinicians to further optimize treatments for the benefit of our patients," Michael Datto, associate VP of DUHS Clinical Laboratories, said in a statement.

Earlier this year, PGDx raised $103 million in Series C funding that it has been using to expand its commercial infrastructure and forge new agreements with diagnostic and pharmaceutical partners.